Should DPD analysis be required prior to prescribing fluoropyrimidines?

European Journal of Cancer

Volumn 43, Issue 6, 2007, Pages 1011-1016

  Yen, Jane L ^a   McLeod, Howard L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

5 Fluorouracil; Capecitabine; Chemotherapy; Dihydropyrimidine dehydrogenase; DPYD; Pharmacogenetics; Pharmacogenomics; Toxicity

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; OXALIPLATIN;

ARTICLE; ASSAY; BREAST CANCER; CANCER; GENE LOCUS; GENETIC SCREENING; HUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); DNA MUTATIONAL ANALYSIS; FLUOROURACIL; HUMANS; MUTATION; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33947588763     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.030     Document Type: Article

References (51)

1. Das P., Lin E.H., Bhatia S., et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 66 (2006) 1378-1383
2. Schmoll H.-J., Cartwright T., Tabernero J., et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol 25 (2007) 102-109
3. Walko C.M., and Lindley C. Capecitabine: a review. Clin Ther 27 (2005) 23-44
4. van Kuilenburg A.B.P., Vreken P., Abeling N.G.G.M., et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104 (1999) 1-9
5. Heggie G.D., Sommadossi J.-P., Cross D.S., Huster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 (1987) 2203-2206
6. van Kuilenburg A.B.P. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40 (2004) 939-950
7. de Bono J.S., and Twelves C.J. The oral fluorinated pyrimidines. Invest New Drugs 19 (2001) 41-59
8. Ishikawa T., Utoh M., Sawada N., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer Xenografts. Biochem Pharmacol 55 (1998) 1091-1097
9. Takai S., Fernandez-Salguero P., Kimura S., Gonzalez F.J., and Yamada K. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization. Genomics 24 (1994) 613-614
10. Wei X., Elizondo G., Sapone A., et al. Characterization of the human dihydropyrimidine dehyrdogenase gene. Genomics 51 (1998) 391-400
11. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J., and Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98 (1996) 610-615
12. Van Kuilenburg A.B.P., Meinsma R., Zoetekouw L., and Van Gennip A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1 G > A mutation. Int J Cancer 101 (2002) 253-258
13. Noguchi T., Tanimoto K., Shimokuni T., et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 10 (2004) 7100-7107
14. Ezzeldin H.H., Lee A.M., Mattison L.K., and Diasio R.B. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11 (2005) 8699-8705
15. Yu J., and McLeod H.L. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 12 (2006) 3864
16. Cancer M-AGI. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-41.
17. Etienne M.C., Lagrange J.L., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12 (1994) 2248-2253
18. Lu Z., Zhang R., Carpenter J.T., and Diasio R.B. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4 (1998) 325-329
19. Sohn D.-R., Cho M.S., and Chung P.-J. Dihydropyrimidine dehydrogenase activity in a Korean population. Ther Drug Monit 21 (1999) 152-154
20. Yamaguchi K., Arai Y., Kanda Y., and Akagi K. Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 92 (2001) 337-342
21. Ogura K., Ohnuma T., Minamide Y., et al. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin Cancer Res 11 (2005) 5104-5111
22. Morsman J.M., Sludden J., Ameyaw M.-M., et al. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol 50 (2000) 269-272
23. Saif M.W., Mattison L., Carollo T., Ezzeldin H., and Diasio R.B. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol 58 (2006) 396-401
24. Hamdy S.I., Hiratsuka M., Narahara K., et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53 (2002) 596-603
25. van Kuilenburg A.B.P., Muller E.W., Haasjes J., et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin Cancer Res 7 (2001) 1149-1153
26. Raida M., Schwabe W., Hausler P., et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of Intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 7 (2001) 2832-2839
27. Salgueiro N., Veiga I., Fragoso M., et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluoruracil toxicity in Portuguese colorectal cancer patients. Genet Med 6 (2004) 102-107
28. Seck K., Riemer S., Kates R., et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of caucasian individuals. Clin Cancer Res 11 (2005) 5886-5892
29. Mattison L.K., Fourie J., Desmond R.A., Modak A., Saif M.W., and Diasio R.B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with caucasians. Clin Cancer Res 12 (2006) 5491-5495
30. Johnson M.R., Yan J., Shao L., Albin N., and Diasio R.B. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr 696 (1997) 183-191
31. van Kuilenburg A.B.P., Van Lenthe H., and Van Gennip A.H. Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography. J Chromatogr B 729 (1999) 307-314
32. van Kuilenburg A., van Lenthe H., and van Gennip A. Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids 25 (2006) 1211-1214
33. Takechi T., Okabe H., Fujioka A., Murakami Y., and Fukushima M. Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn J Cancer Res 89 (1998) 1144-1153
34. Johnson M.R., Wang K., Smith J.B., Heslin M.J., and Diasio R.B. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278 (2000) 175-184
35. Johnson M.R., Wang K., and Diasio R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8 (2002) 768-774
36. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2006 [in press, corrected proof].
37. Furuhata T., Kawakami M., Okita K., et al. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. J Exp Clin Cancer Res 25 (2006) 79-82
38. Morel A., Boisdron-Celle M., Fey L., Laine-Cessac P., and Gamelin E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 40 (2007) 11-17
39. Ciccolini J., Mercier C., Evrard A., et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28 (2006) 678-685
40. Jiang H., Lu J., Jiang J., and Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 44 (2004) 1260-1272
41. Garg M., Sevester J.C., Sakoff J.A., and Ackland S.P. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B 774 (2002) 223-230
42. Mattison L.K., Ezzeldin H., Carpenter M., Modak A., Johnson M.R., and Diasio R.B. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10 (2004) 2652-2658
43. Ezzeldin H., Okamoto Y., Johnson M.R., and Diasio R.B. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidne dehydrogenase deficiency. Anal Biochem 306 (2002) 63-73
44. Ezzeldin H., Johnson M.R., Okamoto Y., and Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 9 (2003) 3021-3028
45. Fischer J., Schwab M., Eichelbaum M., and Zanger U.M. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test 7 (2003) 97-105
46. Ahluwalia R., Freimuth R., McLeod H.L., and Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 49 (2003) 1661-1664
47. Morel A., Boisdron-Celle M., Fey L., et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5 (2006) 2895-2904
48. van Kuilenburg A.B.P., Meinsma R., Zoetekouw L., and van Gennip A.H. High prevalence of the IVS14 + 1G > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12 (2002) 555-558
49. van Kuilenburg A.B.P., Haasjes J., Richel D.J., et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6 (2000) 4705-4712
50. Largillier R., Etienne-Grimaldi M.-C., Formento J.-L., et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 12 (2006) 5496-5502
51. Ciccolini J., Mercier C., Dahan L., et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 58 (2006) 272-275